Literature DB >> 30032875

Management of rocuronium neuromuscular block using a protocol for qualitative monitoring and reversal with neostigmine.

S R Thilen1, I C Ng2, K C Cain3, M M Treggiari4, S M Bhananker5.   

Abstract

BACKGROUND: Neuromuscular block using subjective monitoring and neostigmine reversal is commonly associated with postoperative residual neuromuscular block. We tested whether a protocol for the management of neuromuscular block that specified appropriate dosing and optimal neostigmine reversal was associated with a reduction in postoperative residual neuromuscular block.
METHODS: Rocuronium administration was guided by surgical requirements and based on the ideal body weight, with dose reductions for female sex and age >55 yr. Neostigmine was administered in adjusted doses after a train-of-four count of four was confirmed at the thumb. The protocol ensured a minimum of 10 min between neostigmine administration and tracheal extubation. We measured the postoperative residual neuromuscular block in patients undergoing abdominal surgery before and after introduction of the protocol. Pre-specified primary and secondary endpoints were incidence of postoperative residual neuromuscular block and severe postoperative residual neuromuscular block at the time of tracheal extubation, defined as normalised train-of-four ratios <0.9 and <0.7, respectively.
RESULTS: The incidence of postoperative residual neuromuscular block at tracheal extubation was 14/40 (35%) for patients managed according to the protocol compared with 22/38 (58%) for patients in the control group, odds ratio of 0.39, and 95% confidence interval of 0.14-1.07; P=0.068. The incidence of severe postoperative residual neuromuscular block at tracheal extubation showed a highly significant difference, odds ratio=0.06, and confidence interval of 0.00-0.43; P=0.001.
CONCLUSIONS: The incidence of severe postoperative residual neuromuscular block was significantly reduced after the protocol was introduced. Given the limitations inherent in this before-and-after study, further research is needed to confirm these results. CLINICAL TRIAL REGISTRATION: NCT02660398.
Copyright © 2018 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  muscle weakness/chemically induced; neostigmine; neuromuscular blocking agents; rocuronium

Mesh:

Substances:

Year:  2018        PMID: 30032875     DOI: 10.1016/j.bja.2018.03.029

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  5 in total

1.  [Neuromuscular residual block : Unavoidable risk or reliably treatable?]

Authors:  T Fuchs-Buder
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

2.  Effect of a Cognitive Aid on Reducing Sugammadex Use and Associated Costs: A Time Series Analysis.

Authors:  Dan M Drzymalski; Roman Schumann; Frank J Massaro; Agnieszka Trzcinka; Ruben J Azocar
Journal:  Anesthesiology       Date:  2019-11       Impact factor: 7.892

3.  Usefulness of intra-operative neuromuscular blockade monitoring and reversal agents for postoperative residual neuromuscular blockade: a retrospective observational study.

Authors:  Gonzalo Domenech; Matías A Kampel; María E García Guzzo; Delfina Sánchez Novas; Sergio A Terrasa; Gustavo Garcia Fornari
Journal:  BMC Anesthesiol       Date:  2019-08-07       Impact factor: 2.217

4.  Neuromuscular block in patients 80 years and older: a prospective, controlled study.

Authors:  Denis Schmartz; Raouf Sghaier; Paul Bernard; Jean François Fils; Thomas Fuchs-Buder
Journal:  BMC Anesthesiol       Date:  2021-09-13       Impact factor: 2.217

5.  Vigilance: the behavioral impact of quantitative monitoring on administration and antagonism of neuromuscular blocking agents.

Authors:  Anastasia D Grivoyannis; Virginia Tangel; Cynthia A Lien
Journal:  J Clin Monit Comput       Date:  2021-06-22       Impact factor: 1.977

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.